Posts for tag: Anaphylaxis
Auvi-Q is once again available for life-threatening allergic emergencies_anaphylaxis. This automatic systen delivers adrenalin (epinephrine) to reverse serious allergic reactions. This is a cool device and talks you through the steps of administration. It delivers one dose only. The most useful feature of this device is that it is easily carried in an adolescent's pocket or a parent's purse.
Alternative adrenalin devices are the EpiPen and the generic Adrenaclick. All deliver adrenalin. Only Auvi-Q has an audio system of real-time instruction when needed and is easily pocket-portable. Price and insurance coverage are also factors in your choice of which to carry.
Recommendations are for an individual to have access to two auto injectors, NOT just one, and after use, to seek emergency care quickly for further evaluation and treatment. All units require a doctor's prescription.
Persons with serious life-threatening allergic reactions ALWAYS need to be prepared.
Sanofi US Recalls All Auvi-Q Epinephrine Injection in 2015;
Available Again in 2017!
Sanofi US is voluntarily recalling all of its epinephrine injection (Auvi-Q) on the market because patients taking it for life-threatening anaphylaxis may receive an inaccurate and inadequate dose, the US Food and Drug Administration (FDA) announced today.
The company has received 26 unconfirmed reports of suspected device malfunction from patients in the United States and Canada as of October 26. No one died as a result, but patients continued to experience symptoms of underlying hypersensitivity reaction, the FDA said in a news release.
The agency said that patients using Auvi-Q should ask their physician to prescribe an alternate epinephrine autoinjector. If patients experience anaphylaxis, they should only use Auvi-Q if no other epinephrine autoinjector is available, and then seek emergency medical care.
Auvi-Q is distributed in packs that contain two active injectors, along with a training injector. There are roughly 490,000 packs of Auvi-Q on the market, all of them subject to the recall, Paul Chew, MD, Sanofi's global chief medical officer, told Medscape Medical News. Some packs contain epinephrine injection at 0.15 mg strength, and others at 0.3 mg strength.
The recall includes Auvi-Q packs in lots numbered 2299596 through 3037230, which expire March 2016 through December 2016.
Sanofi customers with questions about the voluntary recall, including how to return the product, can go to the Auvi-Q website or call 1-866-726-6340. More information about the recall is available on the FDA website.
To report any problems with Auvi-Q epinephrine injection, contact MedWatch, the FDA's safety information and adverse event reporting program, by telephone at 1-800-FDA-1088; by fax at 1-800-FDA-0178; online athttps://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm; with postage-paid FDA form 3500, available at http://www.fda.gov/MedWatch/getforms.htm; or by mail to MedWatch, 5600 Fishers Lane, Rockville, Maryland 20852-9787.